Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Anti-dyslipidemic and Antioxidant Potentials of Methanol Extract of Kalanchoe crenata Whole Plant in Streptozotocin-induced Diabetic Nephropathy in Rats

Foyet Angèle Fondjo¹, René Kamgang^1,2 , Jean-Louis Essame Oyono^2,3, Jeanne Ngongang Yonkeu³

¹General Endocrinology and Metabolism Systems (GEMS), Laboratory of Animal Physiology, University of YaoundÃ© I; ²Laboratory of Endocrinology and Radioisotopes, Institute of Medical Research and Medicinal Plants Studies; ³Faculty of Medicine and Biomedical Sciences, University of YaoundÃ© I, Cameroon.

For correspondence:- René Kamgang Email: gemskruy@yahoo.fr Tel:+23777045000

Received: 18 November 2011 Accepted: 14 August 2012 Published: 18 October 2012

Citation: Fondjo FA, Kamgang R, Oyono JE, Yonkeu JN. Anti-dyslipidemic and Antioxidant Potentials of Methanol Extract of Kalanchoe crenata Whole Plant in Streptozotocin-induced Diabetic Nephropathy in Rats. Trop J Pharm Res 2012; 11(5):767-775 doi: 10.4314/tjpr.v11i5.10

© 2012 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: The activity of the methanol extract of the whole plant of Kalanchoe crenata (MEKC) was studied for the treatment of diabetes-induced nephropathy in rats.

Methods: Five-day old Wistar rats received a single intraperitoneal streptozotocin injection (90 µg/kg body weight) to induce diabetes. Kidney disease onset in the rats was observed six weeks after diabetes induction. The rats were orally administered MEKC (0, 50 and 68 mg/kg) or glibenclamide (5 mg/kg), once daily for 6 weeks. Blood and urine glucose, proteins, lipids, creatinine, malondialdehyde (MDA), superoxide dismutase (SOD) and catalase (CAT) were then evaluated.

Results: After 6 weeks of treatment, 50 and 68 mg/kg MEKC, and glibenclamide significantly (p < 0.01) decreased glycaemia (-35, -44 and -39 %), glycosuria (-38, -47 and -61 %) and proteinuria (-82, -80 and -72 %) in diabetes-nephropathic rats. The extract (68 mg/kg) decreased MDA by up to -44 % (blood), -35 % (liver) and -34 % (kidney); increased SOD up to 257 % (blood), 116 % (liver) and 118 % (kidney); and CAT by up to 176 % (blood), 78 % (liver) and 96 % (kidney) in the rats, compared with nephropathic control. The extract (50 and 68 mg/kg, respectively) lowered (p < 0.01) total cholesterolemia (-24 and -27 %), blood triglycerides (-55 and -54 %), blood LDL cholesterol (-48 and -59 %), but increased blood HDL cholesterol (71 and 58 %). Overall, atherogenic index was decreased by 31 %.

Conclusion: The results indicate that MEKC holds promise for the development of a standardized phytomedicine for diabetes mellitus and kidney disease treatment.

Keywords: Diabetes, Dyslipidemia, Antioxidant, Kalanchoe crenata extract, Nephropathy